In today’s briefing:
- Ajanta Pharma (AJP IN): Branded Generics Focus Ensures Consistent Growth
- HHC: Tower Opening Affirms FFO Outlook
- 83: Initial Thoughts On Sherwin-Williams (SHW)
Ajanta Pharma (AJP IN): Branded Generics Focus Ensures Consistent Growth
- Ajanta Pharma (AJP IN) has a well-diversified business model in terms of markets and therapies. The company’s largest revenue contributing segment, branded generics is seeing healthy double-digit revenue growth.
- Ajanta focuses on limited competition product in US. Going forward, the US business will see accelerated growth, driven by new launches. Ajanta plans to file 10–12 ANDAs during FY23.
- Ajanta has taken 1% price increase across all its market, which should drive margin improvement in coming quarters. The company has guided for EBITDA margin of 26–27% for FY23.
HHC: Tower Opening Affirms FFO Outlook
- HHC. announced the opening of 565-unit Ward Village development, Ko’ula. HHC had been forecasting the opening of the new tower at Ward Village since last year
- The opening results in HHC recognizing revenue from the sale of each unit within the tower. The opening of Ko’ula affirms our outlook for the year
- The opening of Ko’ula puts HHC on pace to meet 2022 condo sales guidance of $650 million to $700 million
83: Initial Thoughts On Sherwin-Williams (SHW)
- I’m currently working on the September issue of Watchlist Deep Dives, which features Sherwin-Williams.
- My research process is primary-sources focused and that means reading lots of 10K’s, which include a report from the company’s auditors.
- I was surprised to see that Ernst & Young had served as SHW’s auditor since 1908.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
